and internal BRT efforts, the Company has grown a large library of
human brown fat stem cells. The ThermoStem® Program, which is in the
pre-clinical stage, focuses on the development of therapies using adult
derived stem cells from brown adipose tissue to treat metabolic and
obesity related disorders (particularly focusing on Type 2 Diabetes).
The compilation of a large number and variety of brown fat derived stem
cells allows BRT to study and identify potential cell lines to be used
in developing therapies.Recent published reports have demonstrated that BAT is found in adults and can be routinely isolated. In addition to providing material needed to further advance BRTs pre-clinical models, BioRestorative Therapies' library of stem cells can also provide a valuable and unique resource
in seeking to develop small molecules that activate brown fat and
increase energy expenditure, a strategy for addressing both obesity and
diabetes. The Company's ongoing cell characterizations, collected data,
and stem cells represent a potential supply of necessary controls and
variety of cells for pharmaceutical and other companies embarking on the
small molecule drug development pathway.Mark Weinreb, Chairman and CEO of BioRestorative Therapies, said, "To our knowledge, we have the largest library of human brown fat stem cell lines known, which represents an enormous research asset in working towards a therapy for metabolic disorders and obesity. Having a large collection of brown fat stem cell lines will be important to accelerate the development of our ThermoStem® Program. Such access also provides opportunities for collaboration and strategic partnerships, because this volume and variety of collections is complementary to large pharmaceutical companies working on small molecule-based programs seeking to treat these disorders."
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. ("BRT"), www.biorestorative.com, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives:
- brtxDISC™ Program (Disc Implanted Stem Cells), a non-surgical treatment for bulging and herniated discs that addresses the gap between non-invasive and invasive back procedures. This research is still in the non-clinical, investigational stage.
- ThermoStem® Program, a treatment for metabolic disorders (diabetes, heart disease, etc.) and obesity using brown fat stem cells. Initial non-clinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels in the body.
- brtx-C Cosmetic Program, based on the development of a human cellular extract that, per initial in vitro studies, when applied to human skin cells, appears to cause an increase in the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.
under the Stem Pearls® brand at www.stempearls.com.This press release and the interview contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
Investor Contact:
Adam Holdsworth
ProActive Capital
646.862.4607
adamh@proactivecapital.com
Media Contact:
Sandra Lee
ProActive Capital
646.862.4608
slee@proactivecapital.com
Disclaimer /Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment
involves risk.http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online
advertising. Disclosure: BioRestorative
has compensated Investoridea for a six month news program ( five
thousand ) to be published on Investorideas.com newswire and syndication
and social media partners.BC Residents and Investor
Disclaimer: Effective September 15 2008 - all BC investors should
review all OTC and Pink sheet listed companies for adherence in new
disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894
No comments:
Post a Comment